A Phase 1, Two-part, Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Liquid Formulation of Tricaprilin and Matching Placebo in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

August 13, 2022

Study Completion Date

October 24, 2022

Conditions

Alzheimer Disease

Interventions

DRUG

AC-OLE-01-VA

formulation of tricaprilin or matching placebo

Trial Locations (1)

Quotient Sciences Miami, Miami